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Objectives
The aim of the study was to examine baseline neurocognitive impairment (NCI) prevalence and
factors associated with NCI among patients enrolled in the Neurocognitive Assessment in the
Metabolic and Aging Cohort (NAMACO) study.
Methods
The NAMACO study is an ongoing, prospective, longitudinal, multicentre and multilingual
(German, French and Italian) study within the Swiss HIV Cohort Study. Between 1 May 2013 and
30 November 2016, 981 patients ≥ 45 years old were enrolled in the study. All underwent
standardized neuropsychological (NP) assessment by neuropsychologists. NCI was diagnosed using
Frascati criteria and classified as HIV-associated or as related to other factors. Dichotomized
analysis (NCI versus no NCI) and continuous analyses (based on NP test z-score means) were
performed.
Results
Most patients (942; 96.2%) had viral loads < 50 HIV-1 RNA copies/mL. NCI was identified in 390
patients (39.8%): 263 patients (26.8%) had HIV-associated NCI [249 patients (25.4%) had
asymptomatic neurocognitive impairment (ANI)] and 127 patients (13%) had NCI attributable to
other factors, mainly psychiatric disorders. There was good correlation between dichotomized and
continuous analyses, with NCI associated with older age, non-Caucasian ethnicity, shorter duration
of education, unemployment and longer antiretroviral therapy duration.
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Conclusions
In this large sample of aging people living with HIV with well-controlled infection in Switzerland,
baseline HIV-associated NCI prevalence, as diagnosed after formal NP assessment, was 26.8%, with
most cases being ANI. The NAMACO study data will enable longitudinal analyses within this
population to examine factors affecting NCI development and course.
Keywords: aging, HIV-associated neurocognitive disorder, neurocognitive impairment,
neuropsychological testing
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Introduction
The availability of safe and effective antiretroviral ther-
apy (ART) for HIV infection has enabled people living
with HIV (PLWH) to age. As the population of older
PLWH increases, so does the prevalence of comorbidities.
One such comorbidity, neurocognitive impairment (NCI),
has been described since the start of the HIV epidemic,
but the spectrum post-ART has changed. HIV-associated
dementia (HAD), previously seen in advanced HIV dis-
ease, is now uncommon [1,2], while the prevalence of
milder NCI, which may be asymptomatic, has increased
[3]. Moreover, the presentation of NCI has changed. In
the pre-ART era, HAD was subcortical, rapidly progres-
sive, and characterized by psychomotor slowing, motor
dysfunction and extrapyramidal signs. In the current ART
era, NCI is both cortical and subcortical, relatively stable
over time, and characterized by impairments in working
memory and executive function [4–6].
To reflect this shift, the diagnostic nomenclature of
HIV-associated NCI was revised in 2007 to define stages
of impairment according to the so-called Frascati criteria
[7]. In increasing severity, the stages are: asymptomatic
neurocognitive impairment (ANI), corresponding to mild
to moderate neurocognitive deficits without repercussions
in activities of daily living (ADL); mild neurocognitive
disorders (MNDs), corresponding to mild to moderate
neurocognitive deficits with repercussions in ADL; and
HIV-associated dementia (HAD), corresponding to moder-
ate to severe neurocognitive deficits with repercussions in
ADL [7]. Diagnosing NCI as specifically HIV-associated
requires the exclusion of confounding factors, such as
psychiatric disorders and organic cerebral pathology [7].
Despite these definitions, the NCI literature can be con-
fusing. Firstly, ANI, MNDs and HAD may be referred to
collectively as HIV-associated neurocognitive disorders
(HANDs) if ADL have been assessed [4], or as mild or
moderate NCI if the assessment is based on NP testing
alone [8]. Secondly, some patient populations make up
cohorts designed from the start to study NCI [3,9], or else
subcohorts of long-standing cohorts [10], whereas other
populations are pooled from larger studies designed
originally to answer different clinical questions [8,11].
Thirdly, the level of HIV control is not uniform: some
cohorts group patients together, regardless of HIV viral
load or whether or not they are on ART, while others
exclude patients with detectable viraemia.
In Switzerland, the Neurocognitive Assessment in the
Metabolic and Aging Cohort (NAMACO) study was set up
as a longitudinal study to examine NCI within a well-
characterized and well-treated cohort of PLWH, the Swiss
HIV Cohort Study (SHCS) cohort [12]. In the current
study, we present the characteristics of NAMACO study
patients and the baseline prevalence of NCI.
Methods
The NAMACO study
The NAMACO study is an ongoing, prospective, longitudi-
nal, multicentre and multilingual (German, French and
Italian) study included within an observational open
research cohort study, the SHCS. Since 1988, the SHCS
has collected data at twice-yearly standardized SHCS clinic
visits on the demography, behaviour, medical history (HIV
and non-HIV), HIV infection parameters, treatments and
comorbidities of all enrolled patients aged ≥ 18 years [12].
The NAMACO study was set up to examine the cogni-
tive and neurological impact of HIV infection in an aging
HIV-positive population and has been established in col-
laboration with physicians, neuropsychologists, neurolo-
gists and study nurses.
Standard protocol approvals, registrations and patient
consents
The ethics committees of each cantonal hospital centre
approved the NAMACO study protocol and all patient par-
ticipants signed informed consent prior to being included.
Patient population and study design
The NAMACO study had the following inclusion criteria:
HIV-positive status, age ≥ 45 years, enrolment in the
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SHCS, engagement in care at one of seven cantonal uni-
versity-affiliated hospital centres (Basel, Bern, Geneva,
Lausanne, Lugano, St Gallen and Zurich) and sufficient
oral fluency in the local language to enable neuropsycho-
logical (NP) tests to be performed. SHCS-affiliated infec-
tious disease physicians received a list of eligible patients
attending their clinics and were responsible for inviting
patients to participate in the NAMACO study between 1
May 2013 and 30 November 2016. Enrolment was dis-
continued at 981 patients. Nonenrolment of eligible
patients was related to manpower at each site; as age and
language were the only limiting criteria beyond the need
to be seen at a university-affiliated SHCS centre, patients
were not, in principle, disproportionately selected on the
basis of neurocognitive symptoms or previous neurologi-
cal history.
While all SHCS patients are asked European AIDS Clin-
ical Society (EACS) screening questions on memory, rea-
soning and attention difficulties [13] at their twice-yearly
cohort visits, NAMACO study patients also undergo a
standardized NP assessment at baseline and again at 2
(2016–2018) and 4 years (2018–2020). For all NAMACO
study patients, regardless of their EACS screening ques-
tion responses, NP assessment is performed by either a
neuropsychologist or a neurologist trained in behavioural
neurology and working under the supervision of a neu-
ropsychologist.
As part of the study, patients with NCI are invited to
undergo further investigations according to EACS guide-
lines [14], namely, full neurological examination, cere-
brospinal fluid (CSF) collection via lumbar puncture and
cerebral magnetic resonance imaging (Fig. 1), to examine
the benefit of these interventions as diagnostic tools and
factors associated with NCI.
The current study was a cross-sectional analysis inves-
tigating the neurocognitive status of patients at the time
of enrolment (baseline).
Neurocognitive evaluation
Cognitive complaints
For each of the three EACS screening questions men-
tioned above, the response options are never, hardly ever,
or yes, definitely. Patients answering ‘yes, definitely’ to at
least one question were considered to have cognitive
complaints.
NP assessment
The NP test battery covered seven cognitive domains
known to be affected in HIV-associated NCI (Table 1).
The complete battery required no more than 90 min to
perform if the patient had no deficits. The raw score for
each NP test was converted to a demographically
adjusted standard score (z-score).
The cognitive domains assessed were based on those
used in the International Network for Strategic Initiatives
in Global HIV Trials (INSIGHT) and Strategic Timing of
Antiretroviral Treatment (START) Study Group [8] and
were in accordance with the guidelines published by
Antinori et al. [7]. The tests are sensitive in detecting
NCI, rapid and easy to perform, standardized for several
age and education groups, and available in different lan-
guages. The Hopkins Verbal Learning Test-Revised is par-
ticularly appropriate for longitudinal studies as it
provides six parallel forms to avoid the practice effect at
retest which has been described as a reason for improve-
ment in NP function over time [15,16]. In addition to the
tests used in the START study, we chose to include the
five-point Figural Fluency and the Victoria Stroop test, to
enrich the assessment of executive function, and the
Wechsler adult intelligence scale 4th edition (WAIS-IV)
Digit Span Subtest to assess attention and working mem-
ory (Table 1).
Self-administered assessments
As functional scales are required to differentiate
between ANI and MNDs, Lawton’s Instrumental Activi-
ties of Daily Living (IADL) were assessed [17,18] to
quantify the impact of NCI, if present, on daily func-
tion. Three supplementary questions were added,
inspired by the Patients’ Assessment of Own Function-
ing Inventory questionnaire (a subjective measure of
cognitive function), on professional work quality and
productivity and on relatives’ comments about cogni-
tive decline (Appendix 1). Functional impairment was
defined as difficulties being reported in at least two
items out of 11 (Fig. 2).
Depression severity was graded using the Center for Epi-
demiologic Studies Depression (CES-D) scale by way of a
questionnaire rating mood. Although the CES-D scale has
commonly been used to assess depression among PLWH, it
does have limitations in this setting as some items in the ques-
tionnaire may be related to having HIV infection rather than
depression (items on positive affect and somatic symptoms
such as restless sleep and poor appetite) [19,20]. In the current
study, CES-D scores between 16 and 26 were classed as mild
depression and scores ≥ 27 were classed as severe depression
in order to apply a more stringent depression definition.
NCI definitions and associations
Using the Frascati criteria [7], patients were classified into
five categories as follows (Fig. 2): normal NP examination
(no NCI), ANI, MND, HAD and non-HIV-associated NCI
(‘other’). In patients in the ‘other’ category, NCI was
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attributed to confounding conditions such as substance use,
psychiatric disorders (including severe depression: CES-D
scores ≥ 27), ART toxicity, neurodegenerative disorders,
opportunistic central nervous system (CNS) infection, stroke
history and trauma, rather than to HIV infection (Fig. 2).
Patients with CES-D scores of 16–26 (moderate to severe
low mood) were assigned to the ‘other’ category if the
examining neuropsychologist considered the NP profile to
be related to depression rather than to HIV infection alone.
To identify potential factors associated with NCI, we
examined: demographic factors (age, sex, ethnicity, edu-
cation and employment), HIV-related factors (viral load,
CD4 T-cell count at baseline and nadir CD4 count, dura-
tion of current ART, CPE score at baseline, ART drug
class, namely, nucleoside reverse transcriptase inhibitor,
protease inhibitor, integrase strand transfer inhibitor or
efavirenz, and mode of HIV acquisition), cardiovascular
risk factors [diabetes, hypertension, and total and high-
density lipoprotein (HDL) cholesterol], other comorbidities
(hepatitis B and C, and syphilis), depression score,
cognitive complaints and toxin consumption (smoking,
alcohol use, past injecting drug use, current cannabis use
and current noninjecting cocaine use). Efavirenz use was
analysed individually given the higher rates of neuropsy-
chiatric adverse events associated with this treatment
than with other antiretroviral treatments [21]; treatment
with dolutegravir was not assessed at baseline as this
treatment became available in Switzerland 1 year into the
NAMACO study. All these variables were obtained from
the SHCS database extraction closest in time to each
patient’s neurocognitive assessment. For the current
study, comorbidities and toxin consumption were anal-
ysed as binary (presence or absence) rather than continu-
ous data.
Statistical analysis
Descriptive analyses are presented as mean and standard
deviation (SD) for symmetric continuous variables, as
median and interquartile range (IQR) for asymmetric
981 patients ≥45 years old in the Metabolic and Aging Cohort of the SHCS
All patients assessed at baseline, then at 2 years and at 4 years
Presence of cognitive complaints screened for by physician using EACS screening questions 
(memory loss, mental slowing and attention difficulties)
- Standardized neuropsychological evaluation (7 cognitive domains, shown in Table 1)
- Functional scale (IADL and PAOFI, as described in the text)
- Depression questionnaire (CES-D)
No neurocognitive impairment Neurocognitive impairment
- Full neurological examination
- Brain MRI 
- Lumbar puncture
Fig. 1 Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study design. SHCS, Swiss HIV Cohort Study; EACS, European
AIDS Clinical Society; IADL, Instrumental Activities of Daily Living; PAOFI, Patients’ Assessment of Own Functioning Inventory; CES-D, Center
for Epidemiologic Studies Depression scale; MRI, magnetic resonance imaging.
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continuous variables and as percentages for categorical
variables.
NCI was analysed as a dichotomized and as a continu-
ous variable. For the dichotomized analysis, NCI was
dichotomized as follows: no impairment (no NCI) versus
impairment (ANI, MND, HAD and other). In this setting, a
multivariable logistic regression model was applied to
identify factors associated with NCI occurrence. For the
continuous analysis, NCI was considered as a continuous
variable based on NP test mean z-scores calculated per
domain. The mean of the mean z-scores was calculated
for each patient for five of the seven domains; the two
domains of language and sensory-perceptual skills were
not included in the overall mean z-score calculation as
these domains (1) shared NP tests used for other domains
and (2) were impaired in relatively few patients. For the
continuous analysis, a multivariable linear model was
applied to identify factors associated with a decreased
mean z-score (worse NP performance).
In our analysis, the primary objective was to examine
the prevalence and factors associated with NCI of any
aetiology, HIV-associated and other. We then conducted
a sensitivity analysis, removing patients with other NCI,
to examine only those with specifically HIV-associated
NCI (ANI, MND and HAD).
All analyses were conducted using R Core Team version
2014 (R Foundation for Statistical Computing, Vienna,
Austria; www.R-project.org).
Data availability statement
Anonymized data will be shared by request from any
qualified investigator.
Results
NAMACO patients
Of the 981 patients enrolled, 782 (79.7%) were male, 899
(91.7%) were Caucasian and 627 patients (63.9%) were aged
> 50 years [mean ( SD) age 54.5  7.5 years] (Table 2).
At baseline, most patients (96.2%) had viral loads < 50 HIV-
1 RNA copies/mL; the median CD4 count was 634 cells/lL
(IQR 468, 814 cells/lL) and the median nadir CD4 count was
180 cells/lL (IQR 74, 270 cells/lL) (Table 2).
The percentage of NAMACO patients who were male or
Caucasian was slightly higher than that of SHCS patients
eligible for NAMACO but not enrolled or followed up at
non-NAMACO centres (Table S1).
Prevalence of NCI and cognitive domains affected
Of all 981 patients, 390 (39.8%) presented with NCI, of
whom 263 patients (26.8% of 981) had HIV-associated
NCI and 127 patients (13.0% of 981) had non-HIV-associ-
ated NCI. Examining patients with HIV-associated NCI,
249 patients (25.4% of 981) had ANI, eight patients
(0.8%) had MNDs and six patients (0.6%) had HAD.
Examining the 127 patients with non-HIV-associated
NCI, the majority had a psychiatric disorder (mostly
depression) (79 of 127 patients; 62.2%), a history of sub-
stance use (26 patients; 20.5%), a history of trauma,
stroke or unspecified pathology (32 patients; 25.2%) or
previous opportunistic infections (nine patients; 7.1%).
Taking the 981 patients together, the seven cognitive
domains examined were impaired as follows: motor skills
in 396 patients (41%), speed of information processing in
325 patients (33.1%), attention and working memory in
324 patients (33%), executive function in 240 patients
(24.8%), verbal episodic memory in 169 patients (17.2%),
language in 68 patients (7%) and sensory and perceptual
skills in 56 patients (5.8%) (Fig. 3). These proportions were
similar in patients with HIV-associated NCI and in those
with mild to moderate and severe depression (Fig. 3).
Individual factors associated with NCI
The patient variables associated with NCI were roughly
the same whether the outcome was dichotomized (pres-
ence versus absence of NCI) or considered as a continu-
ous variable (z-scores). The main risk factors for NCI
Table 1 The seven cognitive domains examined and the neuropsy-
chological tests performed in the standardized neuropsychological
assessment of all patients enrolled in the Neurocognitive Assess-
ment in the Metabolic and Aging Cohort (NAMACO) study
Standardized neuropsychological assessment
Cognitive domain Neuropsychological tests
Motor skills Finger Tapping (dominant and nondominant
hands)
Grooved Pegboard (dominant and
nondominant hands)
Speed of information
processing
WAIS-IV, Coding
Colour Trails 1
Attention and working
memory
WAIS-IV Digit Span (forward and backward)
Executive function Category Fluency
5-point Figural Fluency
Victoria Stroop (trial 3 and/or 3/1)
Colour Trails 2
Verbal episodic memory Hopkins Verbal Learning Test – Revised
Language Category Fluency
Victoria Stroop (trial 1)
Sensory and perceptual
skills
Grooved Pegboard (dominant and
nondominant hands)
Victoria Stroop (trial 1)
*WAIS-IV, Wechsler adult intelligence scale 4th edition.
© 2019 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2020), 21, 30--42
34 M Metral et al.
were older age, non-Caucasian ethnicity, shorter duration
of education, unemployment, presence of cognitive com-
plaints, high depression score, longer ART duration and
heterosexual mode of HIV acquisition (Table 3). The ART
duration effect had a significant quadratic form in both
dichotomized and continuous models: the chance of NCI
increased significantly when ART duration increased
(positive linear term), stabilizing with long ART durations
(negative quadratic term); mean z-scores decreased sig-
nificantly when ART duration increased (negative linear
term), stabilizing with long ART durations (positive quad-
ratic term).
Slight differences between the two models were as fol-
lows: a significant protective effect of cannabis was
observed in the continuous model, losing significance
when examined as a dichotomized outcome; unknown
mode of HIV acquisition was a significant risk factor in
the dichotomized model, losing significance when exam-
ined as a continuous outcome; syphilis was a significant
protective factor in the dichotomized model, just not
reaching significance when examined as a continuous
outcome.
In a sensitivity analysis excluding non-HIV-associated
NCI (‘other’) (analysis of 854 patients), we obtained sub-
stantially similar results (Table S2). The differences con-
cerned the depression score, presence of cognitive
complaints and mode of HIV acquisition, which did not
reach significance as risk factors for NCI, while hepatitis
B virus coinfection was a significant risk factor.
Finally, the percentage of NCI in the seven participat-
ing centres was examined according to language.
Although NCI prevalence was observed to be higher in
Potential contributing factors?
Substance use
Psychiatric disorder (diagnosed or CES-D ≥27)
Efavirenz
Neurodegenerative disorder
CNS opportunistic infection
Ischemic stroke
Trauma / unspecified
No Yes
NCI: other
≥1.0 SD below mean 
in≥2 NP domains
ANI
≥1.0 SD below mean 
in≥2 NP domains
NCI: HIV-associated
≥1.0 SD below mean 
in≥2 NP domains
MND
≥1.0 SD below mean 
in≥2 NP domains
HAD
≥2.0 SD below mean 
in≥2 NP domains
No
Yes
IADL
≤9/11
No Yes
NCI present?
Standardized neuropsychological assessment  
(detailed in Table 2)
Fig. 2 Neurocognitive assessment algorithm of the Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study. Neurocog-
nitive impairment was classified according to the Frascati criteria [7] as shown in the boxes with dashed outlines. CNS, central nervous system;
CES-D, Center for Epidemiologic Studies Depression scale; NCI, neurocognitive impairment; NCI, HIV-associated neurocognitive disorder; ANI,
asymptomatic neurocognitive impairment; MND, mild neurocognitive disorder; HAD, HIV-associated dementia; IADL, Instrumental Activities of
Daily Living; SD, standard deviation; NP, neuropsychological.
© 2019 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2020), 21, 30--42
The NAMACO study baseline profile 35
French-speaking compared to German-speaking regions,
this was related to one French-speaking centre having a
higher NCI prevalence than all the other centres and to
one German-speaking centre having a particularly low
NCI prevalence. All NCI rates examined were adjusted for
age, sex, origin, duration of education, mode of HIV
transmission and presence of cognitive complaints to
exclude a patient population effect on NCI. Adjusting for
further patient variables, or examining only HIV-associ-
ated NCI, did not alter this centre effect.
Discussion
In this study, examining a very large and highly charac-
terized cohort of aging HIV-positive individuals with
well-controlled infection, we observe a baseline preva-
lence of HIV-associated NCI (HANDs) of 26.8%. For non-
HIV-associated NCI, the majority of confounding factors
were psychiatric disorders, mainly depression. Older age,
non-Caucasian ethnicity, shorter duration of education,
being unemployed and longer ART duration were the
main factors associated with both HIV- and non-HIV-as-
sociated NCI. These associations were observed using two
different statistical models, considering NCI as a dichoto-
mized and as a continuous variable.
The majority of our patients with NCI had ANI, the
clinical relevance of which has been a matter of debate.
Some researchers argue that NCI prevalence is increasing
merely through the overestimation of impairment among
asymptomatic individuals who, without formal NP test-
ing, would pass as cognitively normal [22,23]. This is
reflected in the EACS guidelines which recommended
screening PLWH regardless of symptoms until 2014 [14]
and then, from 2015, recommended assessing only symp-
tomatic patients [24]. The Mind Exchange Program rec-
ommends screening for cognitive impairment within 6
months of diagnosis but with a different tool from the
three questions recommended by EACS [25]. Other
national guidelines vary in recommendations for screen-
ing and the screening tool used, but all recommend a
comprehensive assessment with exclusion of confounding
factors before a diagnosis of HIV-associated NCI is made
[26].
The clinical relevance of ANI is suggested by virtue of
NCI being a dynamic state, with patients changing NCI
stage with time. Among 347 patients (121 with ANI and
226 neurocognitively normal) enrolled in the CNS HIV
Antiretroviral Therapy Effects Research (CHARTER) study,
having ANI was found to convey a two- to six-fold
increase in the risk of developing symptomatic NCI [27].
Again in the CHARTER study, of 436 patients followed
up over a mean of 35 months, 60.8% were found to
remain neurocognitively stable while the others either
declined or improved [28]. Similarly, among 197 patients
enrolled in the Multicenter AIDS Cohort Study (MACS),
77% remained neurocognitively stable, 13% deteriorated
and 10% improved over a 4-year period [5]. We would
argue that, if NCI stage can change over 2 to 4 years, it
is worth conducting a cohort study where the baseline
Table 2 Demographic, comorbidity and HIV-related data for 981
HIV-positive patients enrolled in the Neurocognitive Assessment in
the Metabolic and Aging Cohort (NAMACO) study
Parameter
Age (years) [mean (SD)] 54.5 (7.5)
Sex (male) [n (%)] 782 (79.7)
Ethnicity [n (%)]
Caucasian 899 (91.7)
Black/other* 81 (8.3)
Education (years) [mean (SD)] 13 (2.8)
Employment [n (%)]
Unemployed (working < 25% of potential work time) 373 (38.0)
Employed part-time (25–75%) 81 (8.3)
Employed full-time (80–100%) 527 (53.7)
Cognitive complaints† [n (%)] 244 (25.1)
CES-D [median (IQR)] 10 (4–17)
Drug use [n (%)]
History of injecting drug use 137 (14.0)
Current cannabis use 103 (10.5)
Current noninjecting cocaine use 16 (1.6)
At-risk alcohol consumption‡ 161 (16.5)
Cardiovascular risk factors
Cigarette smoking [n (%)] 356 (36.4)
Diabetes [n (%)] 59 (6.0)
Hypertension [n (%)] 398 (40.6)
Cholesterol [mean (SD)] 5.1 (1.1)
HDL cholesterol [mean (SD)] 1.4 (0.45)
Coinfections [n (%)]
Hepatitis B virus 460 (46.9)
Hepatitis C virus 171 (17.4)
Syphilis 249 (25.4)
HIV parameters
HIV viral load < 50 copies/mL [n (%)] 942 (96.2)
CD4 count (cells/lL) [median (IQR)] 634 (468–814)
Nadir CD4 count (cells/lL) [median (IQR)] 180 (74–270)
ART duration (years) [median (IQR)] 12.7 (6.5–18)
Current CPE score ≥ 7 [n (%)] 756 (78.9)
ART drug class [n (%)]
Nucleoside reverse transcriptase inhibitor 940 (98.1)
Protease inhibitor 419 (43.7)
Integrase strand transfer inhibitor 259 (27.0)
Efavirenz 203 (21.2)
Likely mode of HIV acquisition [n (%)]
Men who have sex with men 506 (51.6)
Heterosexual 325 (33.1)
Injecting drug use 118 (12.0)
Other/unknown 32 (3.3)
IQR, interquartile range; CES-D, Center for Epidemiologic Studies
Depression scale; HDL, high-density lipoprotein; ART, antiretroviral ther-
apy; CPE, central nervous system penetration effectiveness; SD, standard
deviation.
*59 patients (6%) black; 22 (2.2%) other (non-black, non-Caucasian).
†Answering, ‘Yes, definitely’ to at least one of the three questions.
‡≥ 3 alcoholic drinks per day or ≥ 6 alcoholic drinks in one sitting at
least once a week.
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assessment is sensitive enough to identify patients with
mild or very mild impairment. We would further argue
that, as older individuals are more likely to have NCI
than younger individuals, even with controlled viraemia
[3,29], and as the population of older PLWH is increasing,
studies of NCI should include the widest possible spec-
trum of impairment to gain understanding of how NCI is
likely to evolve. That said, although NP testing remains
the gold standard of NCI diagnosis, it is time-consuming
and costly in resource-limited environments [30]. We
therefore agree with current clinical guidelines on NCI
assessment until research on asymptomatic NCI justifies
change.
Our results differ from those of some other studies in
terms of factors associated with NCI; perhaps this is
related to differences in data collection methods, sample
size and the population analysed. Unlike an Italian study
of 245 asymptomatic HIV-positive patients [31], we did
not observe an association between NCI and cardiovascu-
lar risk factors. However, the Italian patient population
was younger (mean age 46 years) with a higher percent-
age of smokers (54.3%). Nadir CD4 count has been
reported as a predictor of NCI among patients in the
CHARTER study, the Dutch TREVI Cohort study and the
AIDS Clinical Trials Group (ACTG) Longitudinal Linked
Randomized Trials (ALLRT) study [11,32,33]. The fact that
we did not observe this association is possibly related to
the relatively high nadir CD4 count in our population
(median 180 cells/lL); among the French Aquitaine
Cohort of 400 patients, nadir CD4 count (median 260
cells/lL) was also not associated with NCI [34]. Finally,
the negative association we observed between NCI and
syphilis is contrary to the findings of previous studies
and is difficult to explain when CNS inflammation has
been described in the context of neurosyphilis [35,36]. In
our multivariable models, dichotomized and continuous,
each element was examined as an independent variable.
It is possible that the protective effect of syphilis is linked
to a variable that we did not enter into our model;
whether the effect is real will become clearer as the 2-
year and 4-year NAMACO study data are analysed.
Depression was a common confounder in our patients
with NCI. This is not surprising as the depression prevalence
among PLWH is estimated to be two to four times that of
the general population [37]. In depressed individuals, exec-
utive function, speed of information processing, attention
and working memory and verbal episodic memory have
been reported to be impaired [38,39] and this may have
influenced the profile of cognitive domains impaired
among NAMACO study patients overall. Nevertheless, dis-
entangling cognitive disorders as attributable to HIV infec-
tion or to depression is not straightforward, especially
when the profile of NCI observed with both conditions is
similar, that is, of a subcortical nature. This underpins the
value of incorporating the clinical judgement of neuropsy-
chologists in categorizing patients with NCI as having HIV-
associated or other NCI, particularly those with CES-D
scores of 16–26, that is, below the diagnostic cut-off of 27.
The association between depression and neurocognitive
performance is the subject of a separate study within the
NAMACO study population (G Santos, I Locatelli, I Nadin, R
Du Pasquier, KEA Darling, M Cavassini, unpublished data).
This study has limitations. There is a possible recruit-
ment bias among NAMACO study participants compared
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Fig. 3 Percentage of patients with deficits in each of the seven cognitive domains examined by neuropsychological testing. The category ‘All’
refers to all 981 patient participants; the category ‘HIV-associated NCI’ comprised 263 patients diagnosed with an HIV-associated neurocogni-
tive impairment (NCI); the category ‘CES-D > 27’ comprised 90 patients with a Center for Epidemiologic Studies Depression (CES-D) score > 27
and the category ‘CES-D > 16’ comprised 262 patients with a CES-D score > 16.
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to other SHCS patients aged ≥ 45 years. Men who have
sex with men (MSM) and Caucasians, in particular, are
slightly over-represented in the NAMACO study, and this
is probably related to the requirement for NAMACO study
participants to speak the local language to enable perfor-
mance of the neurocognitive tests that require sufficient
verbal knowledge. Patient recruitment depended on
SHCS-affiliated infectious disease physicians who had a
list of eligible patients. Although the study protocol had
clear inclusion criteria, we cannot exclude recruitment
bias related to physicians (degree of involvement with
study, personal judgement as to which patients would be
Table 3 Demographic and clinical associations with neurocognitive impairment in multivariate models applied to 981 HIV-positive patients.
Impairment is presented as a dichotomous variable (multivariate logistic model, left-hand columns) and as a continuous variable (multivariate
linear model, right-hand columns)
Dichotomized analysis Continuous analysis
Odds ratio* P-value 95% CI Effect† P-value 95% CI
Age (years) 1.03 0.020 0.00 0.06 0.01 0.001 0.01 0.00
Sex (male) 1.24 0.393 0.28 0.72 0.09 0.060 0.19 0.00
Ethnicity (ref: Caucasian) 8.80 <0.0001 1.41 3.03 0.64 <0.0001 0.76 0.52
Education 0.85 <0.0001 0.23 0.09 0.04 <0.0001 0.03 0.06
Employment
Part-time (25–75%) (ref: unemployed) 0.57 0.071 1.17 0.04 0.17 0.004 0.05 0.29
Full-time (80–100%) (ref: unemployed) 0.45 <0.0001 1.18 0.40 0.15 <0.0001 0.08 0.23
Cognitive complaints‡ 1.53 0.024 0.05 0.79 0.10 0.005 0.17 0.03
CES-D 1.05 <0.0001 0.03 0.06 0.01 <0.0001 0.01 0.01
Drug use
History of injecting drug use 1.42 0.468 0.60 1.30 0.02 0.809 0.19 0.15
Current cannabis use 0.67 0.170 0.99 0.17 0.12 0.032 0.01 0.22
Current noninjecting cocaine use 1.31 0.709 1.23 1.61 0.01 0.922 0.25 0.23
Alcohol consumption at risk§ 1.05 0.821 0.39 0.48 0.00 0.993 0.08 0.08
Cardiovascular risk factors
Cigarette smoking 1.00 0.999 0.36 0.36 0.04 0.292 0.10 0.03
Diabetes 1.73 0.105 0.11 1.22 0.12 0.064 0.25 0.01
Hypertension 0.82 0.240 0.53 0.13 0.01 0.736 0.05 0.07
Cholesterol 0.98 0.843 0.17 0.14 0.01 0.563 0.02 0.04
HDL cholesterol 1.07 0.745 0.33 0.46 0.03 0.358 0.04 0.11
Coinfections
Hepatitis B virus 1.08 0.812 0.53 0.67 0.06 0.327 0.17 0.06
Hepatitis C virus 1.39 0.065 0.02 0.69 0.04 0.189 0.11 0.02
Syphilis 0.57 0.007 0.98 0.16 0.07 0.051 0.00 0.15
HIV parameters
HIV viral load < 50 copies/mL 0.63 0.285 1.30 0.39 0.02 0.862 0.19 0.16
CD4 count at enrolment 0.97 0.312 0.10 0.03 0.00 0.734 0.01 0.01
Nadir CD4 count 1.01 0.896 0.13 0.14 0.02 0.190 0.04 0.01
ART duration 1.13 0.021 0.02 0.23 0.03 0.002 0.05 0.01
ART duration2 0.99 0.005 0.01 0.00 0.00 0.001 0.00 0.00
Current CPE score ≥ 7 1.20 0.409 0.24 0.61 0.06 0.157 0.14 0.02
ART drug class
Nucleoside reverse transcriptase inhibitor 0.99 0.982 1.17 1.23 0.06 0.604 0.17 0.29
Protease inhibitor 1.34 0.126 0.08 0.67 0.04 0.314 0.11 0.03
Integrase strand transfer inhibitor 0.87 0.505 0.53 0.26 0.01 0.827 0.08 0.07
Efavirenz 0.90 0.651 0.55 0.34 0.02 0.671 0.10 0.07
Likely mode of HIV acquisition
Heterosexual (ref: MSM) 1.97 0.002 0.24 1.12 0.12 0.008 0.20 0.03
Injecting drug use (ref: MSM) 0.62 0.364 1.50 0.54 0.03 0.790 0.16 0.22
Other/unknown (ref: MSM) 3.07 0.013 0.24 2.02 0.13 0.149 0.30 0.05
CI, confidence interval; SD, standard deviation; IQR, interquartile range; CES-D, Center for Epidemiologic Studies Depression scale; HDL, high-density
lipoprotein; ART, antiretroviral therapy; CPE, central nervous system penetration effectiveness; MSM, men who have sex with men.
P-values < 0.05 are shown in bold text.
*Odds ratios with P-values from a multivariate logistic model based on a binary outcome of neurocognitive impairment: no impairment (0) versus
impairment (> 0).
†Difference in mean z-score.
‡Answering, ‘Yes, definitely’ to at least one of the three questions.
§≥ 3 alcoholic drinks per day or ≥ 6 alcoholic drinks in one sitting at least once a week.
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suitable participants or who ‘should’ be assessed) or to
patients (more/less willing to participate if cognitively
symptomatic). We presented NCI diagnosis according to
the Frascati criteria to enable comparison between our
patient population and other cohorts. However, we
acknowledge that applying other diagnostic criteria might
have classified our patients differently. The low number
of patients with MNDs in particular is surprising and may
be related to the relatively low sensitivity of functional
impairment scales which differentiate between MNDs and
ANI. In our future analysis within the NAMACO study,
notably the 2-year follow-up, we will focus on patient z-
scores rather than on Frascati-based NCI labels. In order
to dovetail the NAMACO study with a database that
extensively characterizes each patient in terms of ART
history and other HIV- and non-HIV-related variables,
patients needed to be enrolled in the SHCS and followed
up regularly in larger hospital centres. Against these limi-
tations, the NAMACO study did not focus on enrolling
only patients with cognitive complaints and has a large
patient cohort designed specifically to study NCI. More-
over, this study reflects the cognitive status of PLWH
aged ≥ 45 years in the whole of Switzerland, which
means that the cognitive battery had to be administered
in three languages: German, French and Italian. Such an
achievement required NP test validation in three lan-
guages. To the best of our knowledge, this is the first
neuropsychological study (in any field, not only HIV) to
assess patients in parallel in the three linguistic regions
of Switzerland. In addition to the large cohort, the link to
the SHCS makes the NAMACO study database a high-
quality resource with which to examine factors important
in determining NCI prevalence, incidence and course.
In conclusion, we observed that over a quarter of
aging patients (≥ 45 years old) enrolled in the NAMACO
study had HIV-associated NCI, a proportion that may
increase as our patient cohort ages, despite optimal viral
suppression. Among patients with non-HIV-associated
NCI, psychiatric disorders, particularly depression, were
prevalent. The longitudinal analysis of NAMACO study
participants at 2 and 4 years from baseline will shed
light on how NCI develops and may be modified in our
cohort.
Acknowledgements
We thank all the patients participating in the NAMACO
study. We thank all the infectious disease physicians and
the study nurses working in the centres for their dedicated
patient work and contribution to the NAMACO study. We
thank the neuropsychologists Samanta Simioni, Severin
Fr€uh, Stefanie Clarke and Stefania Rossi, for their work in
NAMACO. Finally, we thank Dr Kevin Robertson for his
advice regarding the selection of cognitive tests and his
encouragement to launch the study. The NAMACO study
group: director: Matthias Cavassini; co-director: Renaud
Du Pasquier; neuropsychologists: Melanie Metral, Samanta
Simioni, Peter Brugger, Klemens Gutbrod, Andreas U.
Monsch, Ursi Kunze, Marianne Schneitter, Isaure Nadin,
Severin Fr€uh, Marc Schwind, Riccardo Pignatti and Ste-
fanie Clarke; neurologists: Frederic Assal, Tobias Derfuss,
Sebastian von Arx, G€unter Eisele, Leonardo Sacco, Manuel
Bertschi, Thomas Hundsberger and Renaud Du Pasquier;
infectious disease specialists: Alexandra Calmy, Thanh
Doco Lecompte, Christoph Hauser, Alexia Cusini, Rainer
Weber, Helen Kovari, Barbara Hasse, Philip Tarr, Marcel
Stoeckle, Christoph Fux, Enos Bernasconi, Caroline Di Ben-
edetto, Alessandra Bruno, Patrick Schmid, Katharine Dar-
ling and Matthias Cavassini; SHCS data centre: Alexandra
Scherrer; data management unit: Alexandra Scherrer, Yan-
nick Vallet and Deolinda Alves; statistician: Isabella Loca-
telli; pharmacologist: Laurent Decosterd; neuro-imaging
specialists: Cristina Granziera, Gunnar Krueger, Reto Meuli
and Maria Vargas.
Conflicts of interest: KEAD’s institution has received
research funding unrelated to this publication from
Gilead and sponsorship for specialist meetings from MSD.
A. Cusini has received travel grants and meeting expenses
from MSD, BMS, Gilead and Astellas paid to her institu-
tion. PET’s institution has received research grants and
advisory fees from ViiV and Gilead. A. Calmy’s institu-
tion has received unrestricted education grants from Abb-
Vie, Gilead, MSD and ViiV. CDB has received sponsorship
for specialist meetings from Janssen-Cilag and AbbVie.
RDP is a board member at Gilead. MC’s institution has
received a research grant from ViiV and Gilead and
offered expert testimony for AbbVie, MSD, Gilead and
Sandoz. The other authors report no conflicts of interest.
Financial disclosure: The NAMACO study is supported
by the Swiss National Science Foundation (grant number
163348) and the Swiss HIV Cohort Study (grant number
148522, project 811). Additional funding has been pro-
vided by the Swiss HIV Cohort Foundation and ViiV
Healthcare.
Disclaimer
The opinions expressed in this article are those of the
authors and do not necessarily represent those of ViiV.
ViiV had no role in the study design, data collection and
analysis, decision to publish, or preparation of the manu-
script.
© 2019 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2020), 21, 30--42
The NAMACO study baseline profile 39
Author contributions
MC, RDP, PT and A. Calmy designed the study. MM, IL,
IN and GS finalized the neuropsychologist database. IL
performed the statistical analysis. MC and RDP supervised
the study. MM and KEAD wrote the manuscript. All
investigators contributed to data collection and interpre-
tation, reviewed drafts of posters and the manuscript, and
approved the final manuscript.
References
1 McArthur JC, Brew BJ, Nath A. Neurological complications
of HIV infection. Lancet Neurol 2005; 4: 543–555.
2 Bhaskaran K, Mussini C, Antinori A et al. Changes in the
incidence and predictors of human immunodeficiency virus-
associated dementia in the era of highly active antiretroviral
therapy. Ann Neurol 2008; 63: 213–221.
3 Heaton RK, Clifford DB, Franklin DR Jr et al. HIV-associated
neurocognitive disorders persist in the era of potent
antiretroviral therapy: CHARTER Study. Neurology 2010; 75:
2087–2096.
4 Heaton RK, Franklin DR, Ellis RJ et al. HIV-associated
neurocognitive disorders before and during the era of
combination antiretroviral therapy: differences in rates,
nature, and predictors. J Neurovirol 2011; 17: 3–16.
5 Sacktor N, Skolasky RL, Seaberg E et al. Prevalence of HIV-
associated neurocognitive disorders in the Multicenter AIDS
Cohort Study. Neurology 2016; 86: 334–340.
6 Sacktor N. Changing clinical phenotypes of HIV-associated
neurocognitive disorders. J Neurovirol 2018; 24: 141–145.
7 Antinori A, Arendt G, Becker JT et al. Updated research
nosology for HIV-associated neurocognitive disorders.
Neurology 2007; 69: 1789–1799.
8 Wright EJ, Grund B, Cysique LA et al. Factors associated
with neurocognitive test performance at baseline: a substudy
of the INSIGHT strategic timing of antiretroviral treatment
(START) trial. HIV Med 2015; 16 (Suppl 1): 97–108.
9 Bagkeris E, Burgess L, Mallon PW et al. Cohort profile: the
pharmacokinetic and clinical observations in people over
fifty (POPPY) study. Int J Epidemiol 2018; 47: 1391–1392e.
10 Becker JT, Kingsley LA, Molsberry S et al. Cohort profile:
recruitment cohorts in the neuropsychological substudy of
the multicenter AIDS cohort study. Int J Epidemiol 2015; 44:
1506–1516.
11 Robertson KR, Smurzynski M, Parsons TD et al. The
prevalence and incidence of neurocognitive impairment in
the HAART era. AIDS 2007; 21: 1915–1921.
12 Schoeni-Affolter F, Ledergerber B, Rickenbach M et al.
Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol
2010; 39: 1179–1189.
13 Simioni S, Cavassini M, Annoni JM et al. Cognitive
dysfunction in HIV patients despite long-standing
suppression of viremia. AIDS 2010; 24: 1243–1250.
14 European Aids Clinical Society Guidelines Version 7.1.
Available at http://www.eacsociety.org/files/guidelines_e
nglish_71_141204.pdf. 2014 (accessed 1 July 2019).
15 Heilbronner RL, Sweet JJ, Attix DK, Krull KR, Henry GK,
Hart RP. Official position of the American Academy of
Clinical Neuropsychology on serial neuropsychological
assessments: the utility and challenges of repeat test
administrations in clinical and forensic contexts. Clin
Neuropsychol 2010; 24: 1267–1278.
16 Grund B, Wright EJ, Brew BJ et al. Improved neurocognitive
test performance in both arms of the SMART study: impact
of practice effect. J Neurovirol 2013; 19: 383–392.
17 Lawton MP, Brody EM. Assessment of older people: self-
maintaining and instrumental activities of daily living.
Gerontologist 1969; 9: 179–186.
18 Heaton RK, Marcotte TD, Mindt MR et al. The impact of HIV-
associated neuropsychological impairment on everyday
functioning. J Int Neuropsychol Soc 2004; 10: 317–331.
19 Gay CL, Kottorp A, Lerdal A, Lee KA. Psychometric
limitations of the center for epidemiologic studies-depression
scale for assessing depressive symptoms among adults with
HIV/AIDS: a Rasch analysis. Depress Res Treat 2016; 2016:
2824595.
20 Simoni JM, Safren SA, Manhart LE et al. Challenges in
addressing depression in HIV research: assessment, cultural
context, and methods. AIDS Behav 2011; 15: 376–388.
21 Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric
adverse events during clinical trials of efavirenz in
antiretroviral-naive patients: a systematic review. AIDS Rev
2010; 12: 67–75.
22 Gisslen M, Price RW, Nilsson S. The definition of HIV-
associated neurocognitive disorders: are we overestimating
the real prevalence? BMC Infect Dis 2011; 11: 356.
23 Underwood J, De Francesco D, Leech R et al. Medicalising
normality? Using a simulated dataset to assess the
performance of different diagnostic criteria of HIV-
associated cognitive impairment. PLoS ONE 2018; 13:
e0194760.
24 European AIDS Clinical Society Guidelines Version 8.0.
Available at http://www.eacsociety.org/files/guidelines_8_0-
english_web.pdf. 2015 (accessed 1 July 2019).
25 Mind Exchange Working G. Assessment, diagnosis, and
treatment of HIV-associated neurocognitive disorder: a
consensus report of the mind exchange program. Clin Infect
Dis 2013; 56: 1004–1017.
26 Underwood J, Winston A. Guidelines for evaluation and
management of cognitive disorders in HIV-positive
individuals. Curr HIV/AIDS Rep 2016; 13: 235–240.
© 2019 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2020), 21, 30--42
40 M Metral et al.
27 Grant I, Franklin DR Jr, Deutsch R et al. Asymptomatic HIV-
associated neurocognitive impairment increases risk for
symptomatic decline. Neurology 2014; 82: 2055–2062.
28 Heaton RK, Franklin DR Jr, Deutsch R et al. Neurocognitive
change in the era of HIV combination antiretroviral therapy:
the longitudinal CHARTER study. Clin Infect Dis 2015; 60:
473–480.
29 Coban H, Robertson K, Smurzynski M et al. Impact of aging
on neurocognitive performance in previously antiretroviral-
naive HIV-infected individuals on their first suppressive
regimen. AIDS 2017; 31: 1565–1571.
30 Carroll A, Brew B. HIV-associated neurocognitive disorders:
recent advances in pathogenesis, biomarkers, and treatment.
F1000Research 2017; 6: 312.
31 Fabbiani M, Ciccarelli N, Tana M et al. Cardiovascular risk
factors and carotid intima-media thickness are associated
with lower cognitive performance in HIV-infected patients.
HIV Med 2013; 14: 136–144.
32 Ellis RJ, Badiee J, Vaida F et al. CD4 nadir is a predictor of
HIV neurocognitive impairment in the era of combination
antiretroviral therapy. AIDS 2011; 25: 1747–1751.
33 van den Dries LWJ, Wagener MN, Jiskoot LC et al.
Neurocognitive impairment in a chronically well-suppressed
HIV-infected population: the Dutch TREVI Cohort study.
AIDS Patient Care STDS 2017; 31: 329–334.
34 Bonnet F, Amieva H, Marquant F et al. Cognitive disorders
in HIV-infected patients: are they HIV-related? AIDS 2013;
27: 391–400.
35 Marra CM, Deutsch R, Collier AC et al. Neurocognitive
impairment in HIV-infected individuals with previous
syphilis. Int J STD AIDS 2013; 24: 351–355.
36 Ho EL, Maxwell CL, Dunaway SB et al. Neurosyphilis
increases human immunodeficiency virus (HIV)-associated
central nervous system inflammation but does not explain
cognitive impairment in HIV-infected individuals with
syphilis. Clin Infect Dis 2017; 65: 943–948.
37 Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L.
Depression in HIV infected patients: a review. Curr
Psychiatry Rep 2015; 17: 530.
38 McDermott LM, Ebmeier KP. A meta-analysis of depression
severity and cognitive function. J Affect Disord 2009; 119:
1–8.
39 Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive
impairment in depression: a systematic review and meta-
analysis. Psychol Med 2014; 44: 2029–2040.
Supporting Information
Additional supporting information may be found online
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Table S1. Patients enrolled in the Swiss HIV Cohort
Study (SHCS) who were recruited to the Neurocognitive
Assessment in the Metabolic and Aging Cohort
(NAMACO) study compared to patients who were eligible
but not recruited and patients followed up at non-
NAMACO centres.
Table S2. Demographic and clinical associations with
neurocognitive impairment in multivariate models
applied to 854 HIV-positive patients (excluding the cate-
gory ‘other’).
Appendix 1 : Instrumental Activities of
Daily Living (IADL) scale
PATIENT ID:__________ DATE OF VISIT: ___________ VISIT N: ____
A. Ability to use telephone
1. Operates telephone on own initiative; looks up and dials numbers 1
2. Dials a few well-known numbers 1
3. Answers telephone but does not dial 1
4. Does not use telephone at all 0
B. Shopping
1. Takes care of all shopping needs independently 1
2. Shops independently for small purchases 0
3. Needs to be accompanied on any shopping trip 0
4. Completely unable to shop 0
C. Food preparation
1. Plans, prepares, and serves adequate meals independently 1
2. Prepares adequate meals if supplied with ingredients 0
3. Heats and serves prepared meals or prepares meals but does not
maintain adequate diet
0
4. Needs to have meals prepared and served 0
D. Housekeeping
1. Maintains house alone with occasional assistance (heavy work) 1
2. Performs light daily tasks such as dishwashing, bed making 1
3. Performs light daily tasks but cannot maintain acceptable level of
cleanliness
1
4. Needs help with all home maintenance tasks 1
5. Does not participate in any housekeeping tasks 0
E. Laundry
1. Does personal laundry completely 1
2. Launders small items, rinses socks, stockings, etc. 1
3. All laundry must be done by others 0
F. Models of transportation
1. Travels independently on public transportation or drives own car 1
2. Arranges own travel via taxi, but does not otherwise use public
transportation
1
3. Travels on public transportation when assisted or accompanied by
another
1
4. Travel limited to taxi or automobile with assistance of another 0
5. Does not travel at all 0
G. Responsibility for own medications
1. Is responsible for taking medication in correct dosages at correct time 1
2. Takes responsibility if medication is prepared in advance in separate
dosages
0
3. Is not capable of dispensing own medication 0
H. Ability to handle finances
1. Manages financial matters independently (budgets, writes checks, pays
rent and bills, goes to bank); collects and keeps track of income
1
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2. Manages day-to-day purchases, but needs help with banking, major
purchases, etc.
1
3. Incapable of handling money 0
Source: see Lawton and Brody [17].
Supplementary questions on job
performance
I. Job performance
1. Unable to perform some aspects of previous job (not due to medical
symptoms)
0
L. Job performance
1. Reduced efficiency or productivity; or more errors or difficulties
meeting expectations; or greater effort to perform the same activities
0
Scoring (TOTAL): if the patient receives a score of 0 for at least two of
the items above (A–L), then s/he is considered to be functionally
impaired.
https://www.sm.ee/sites/default/files/content-editors/eesmargid_ja_tege
vused/Tervis/Ravimid/eacsguidelines_v6.1_nov2012.pdf.
Source: see Lawton and Brody [7].
Supplementary question concerning social
entourage
M. Entourage
1. Comments made by entourage (close family, friends, colleagues, etc.)
regarding decline in cognitive function
0
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